Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- HFpEF in women: A growing public health issue that requires more attention
-
- Getting to the heart of the matter: The new obesity and lifestyle guidelines
- The wait is over: The cholesterol treatment guidelines are here Roger S. Blumenthal, MD; Seth S. Martin, MD, MHS, FACC, FAHA, FASPC
- First leadless pacemaker receives CE mark
- NIH, CDC launch registry for sudden death in youth
- First-in-class MitraClip receives FDA approval
- FDA: Partially hydrogenated oil unsafe for food use due to CV risks
- AHA: Preventive care for elderly patients should be personalized
- Familial hypercholesterolemia underdiagnosed, undertreated worldwide
-
- Metformin failed to improve CV risk factors in patients without diabetes
- New test predicted preeclampsia
- Novel anticoagulant prescriptions on the rise among elderly patients
- SCAI: Medical simulation necessary in interventional cardiology
- Study identifies genetic variants linked to changes in lipid levels
- USPSTF: Evidence on hypertension screening for asymptomatic children inconclusive
- CHILL-MI: Therapeutic hypothermia benefited patients with early anterior STEMI
- CORAL: Renal stenting fails to reduce clinical events vs. medical therapy
-
- CoreValve transcatheter aortic valve decreased mortality, stroke in extreme-risk patients
- EUROMAX: Bivalirudin superior to heparin in pre-hospital setting for patients with STEMI
- FREEDOM: Insulin therapy increased CV risk after revascularization in diabetes
- Galectin-3 strong prognostic marker in patients with pulmonary hypertension
- High-STEACS: Troponin test could improve accuracy of MI diagnosis in women
- Mitral valve repair no better than replacement
- Radial access may be reasonable option for women undergoing PCI
- TOPCAT: Spironolactone failed to improve clinical outcomes in HFpEF
-
- Vascular stent improved quality of life in patients with femoral artery disease
- The current status of amiodarone adverse event monitoring Janice Kim, PharmD candidate; Dave L. Dixon, PharmD, BCPS, CDE, CLS
- ANCHOR
- DUTCH PEERS (TWENTE II)
- INVEST
- LEVANT 2 Registry
- REPRISE II
- SMART-CASE
-